{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:14:49Z","timestamp":1788480889998,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006310","name":"Medicinska Forskningsr\u00e5det","doi-asserted-by":"publisher","award":["2017-02559"],"award-info":[{"award-number":["2017-02559"]}],"id":[{"id":"10.13039\/501100006310","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006310","name":"Medicinska Forskningsr\u00e5det","doi-asserted-by":"publisher","award":["K2014-62X-14647-12-51"],"award-info":[{"award-number":["K2014-62X-14647-12-51"]}],"id":[{"id":"10.13039\/501100006310","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Metabolites of the kynurenine pathway of tryptophan degradation, in particular, the <jats:italic>N<\/jats:italic>-Methyl-<jats:sc>d<\/jats:sc>-aspartic acid receptor antagonist kynurenic acid (KYNA), are increasingly recognized as primary pathophysiological promoters in several psychiatric diseases. Studies analyzing central KYNA levels from subjects with psychotic disorders have reported increased levels. However, sample sizes are limited and in contrast many larger studies examining this compound in blood from psychotic patients commonly report a decrease. A major question is to what extent peripheral KYNA levels reflect brain KYNA levels under physiological as well as pathophysiological conditions. Here we measured KYNA in plasma from a total of 277 subjects with detailed phenotypic data, including 163 BD subjects and 114 matched healthy controls (HCs), using an HPLC system. Among them, 94 BD subjects and 113 HCs also had CSF KYNA concentrations analyzed. We observe a selective increase of CSF KYNA in BD subjects with previous psychotic episodes although this group did not display altered plasma KYNA levels. In contrast, BD subjects with ongoing depressive symptoms displayed a tendency to decreased plasma KYNA concentrations but unchanged CSF KYNA levels. Sex and age displayed specific effects on KYNA concentrations depending on if measured centrally or in the periphery. These findings implicate brain-specific regulation of KYNA under physiological as well as under pathophysiological conditions and strengthen our previous observation of CSF KYNA as a biomarker in BD. In summary, biomarker and drug discovery studies should include central KYNA measurements for a more reliable estimation of brain KYNA levels.<\/jats:p>","DOI":"10.1038\/s41398-019-0378-9","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T13:04:39Z","timestamp":1548767079000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Peripheral and central levels of kynurenic acid in bipolar disorder subjects and healthy controls"],"prefix":"10.1038","volume":"9","author":[{"given":"Carl M.","family":"Sellgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Gracias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Jungholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-6757","authenticated-orcid":false,"given":"Roy H.","family":"Perlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"Engberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilly","family":"Schwieler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Landen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Erhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,29]]},"reference":[{"key":"378_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrn3257","volume":"13","author":"R Schwarcz","year":"2012","unstructured":"Schwarcz, R., Bruno, J. P., Muchowski, P. J. & Wu, H. Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 13, 465\u2013477 (2012).","journal-title":"Nat. Rev. Neurosci."},{"key":"378_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0304-3940(01)02242-X","volume":"313","author":"S Erhardt","year":"2001","unstructured":"Erhardt, S. et al. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 313, 96\u201398 (2001).","journal-title":"Neurosci. Lett."},{"key":"378_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.schres.2005.07.013","volume":"80","author":"LK Nilsson","year":"2005","unstructured":"Nilsson, L. K. et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr. Res. 80, 315\u2013322 (2005).","journal-title":"Schizophr. Res."},{"key":"378_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1503\/jpn.090180","volume":"35","author":"SK Olsson","year":"2010","unstructured":"Olsson, S. K. et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J. Psychiatry Neurosci. 35, 195\u2013199 (2010).","journal-title":"J. Psychiatry Neurosci."},{"key":"378_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/bdi.12009","volume":"14","author":"SK Olsson","year":"2012","unstructured":"Olsson, S. K., Sellgren, C., Engberg, G., Landen, M. & Erhardt, S. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord. 14, 719\u2013726 (2012).","journal-title":"Bipolar Disord."},{"key":"378_CR6","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/mp.2015.186","volume":"21","author":"CM Sellgren","year":"2016","unstructured":"Sellgren, C. M. et al. A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. Mol. Psychiatry 21, 1342\u20131350 (2016).","journal-title":"Mol. Psychiatry"},{"key":"378_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0006-3223(01)01078-2","volume":"50","author":"R Schwarcz","year":"2001","unstructured":"Schwarcz, R. et al. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50, 521\u2013530 (2001).","journal-title":"Biol. Psychiatry"},{"key":"378_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/schbul\/sbq112","volume":"37","author":"KV Sathyasaikumar","year":"2011","unstructured":"Sathyasaikumar, K. V. et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr. Bull. 37, 1147\u20131156 (2011).","journal-title":"Schizophr. Bull."},{"key":"378_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.brainres.2005.12.056","volume":"1073-1074","author":"CL Miller","year":"2006","unstructured":"Miller, C. L., Llenos, I. C., Dulay, J. R. & Weis, S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 1073-1074, 25\u201337 (2006).","journal-title":"Brain Res."},{"key":"378_CR10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1503\/jpn.140126","volume":"40","author":"L Schwieler","year":"2015","unstructured":"Schwieler, L. et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia\u2014significance for activation of the kynurenine pathway. J. Psychiatry Neurosci. 40, 126\u2013133 (2015).","journal-title":"J. Psychiatry Neurosci."},{"key":"378_CR11","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/mp.2009.52","volume":"14","author":"J Soderlund","year":"2009","unstructured":"Soderlund, J. et al. Activation of brain interleukin-1beta in schizophrenia. Mol. Psychiatry 14, 1069\u20131071 (2009).","journal-title":"Mol. Psychiatry"},{"key":"378_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1503\/jpn.100080","volume":"36","author":"J Soderlund","year":"2011","unstructured":"Soderlund, J. et al. Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder. J. Psychiatry Neurosci. 36, 114\u2013118 (2011).","journal-title":"J. Psychiatry Neurosci."},{"key":"378_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.biopsych.2004.06.006","volume":"56","author":"S Erhardt","year":"2004","unstructured":"Erhardt, S., Schwieler, L., Emanuelsson, C. & Geyer, M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol. Psychiatry 56, 255\u2013260 (2004).","journal-title":"Biol. Psychiatry"},{"key":"378_CR14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00213-011-2539-2","volume":"220","author":"KS Alexander","year":"2012","unstructured":"Alexander, K. S., Wu, H. Q., Schwarcz, R. & Bruno, J. P. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology 220, 627\u2013637 (2012).","journal-title":"Psychopharmacology"},{"key":"378_CR15","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/j.1471-4159.1991.tb03460.x","volume":"56","author":"S Fukui","year":"1991","unstructured":"Fukui, S., Schwarcz, R., Rapoport, S. I., Takada, Y. & Smith, Q. R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 56, 2007\u20132017 (1991).","journal-title":"J. Neurochem."},{"issue":"Pt B","key":"378_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuropharm.2016.08.003","volume":"112","author":"R Schwarcz","year":"2017","unstructured":"Schwarcz, R. & Stone, T. W. The kynurenine pathway and the brain: challenges, controversies and promises. Neuropharmacology 112(Pt B), 237\u2013247 (2017).","journal-title":"Neuropharmacology"},{"key":"378_CR17","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1021\/mp300570z","volume":"10","author":"AK Deo","year":"2013","unstructured":"Deo, A. K., Theil, F. P. & Nicolas, J. M. Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states. Mol. Pharm. 10, 1581\u20131595 (2013).","journal-title":"Mol. Pharm."},{"key":"378_CR18","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/schbul\/sbw221","volume":"43","author":"E Plitman","year":"2017","unstructured":"Plitman, E. et al. Kynurenic acid in Schizophrenia: a systematic review and meta-analysis. Schizophr. Bull. 43, 764\u2013777 (2017).","journal-title":"Schizophr. Bull."},{"key":"378_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.88","volume":"7","author":"BE Wurfel","year":"2017","unstructured":"Wurfel, B. E. et al. Serum kynurenic acid is reduced in affective psychosis. Transl. Psychiatry 7, e1115 (2017).","journal-title":"Transl. Psychiatry"},{"key":"378_CR20","first-page":"231","volume":"48","author":"A Ravikumar","year":"2000","unstructured":"Ravikumar, A., Deepadevi, K. V., Arun, P., Manojkumar, V. & Kurup, P. A. Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders. Neurol. India 48, 231\u2013238 (2000).","journal-title":"Neurol. India"},{"key":"378_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172699","volume":"12","author":"A Birner","year":"2017","unstructured":"Birner, A. et al. Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder. PLoS One 12, e0172699 (2017).","journal-title":"PLoS One"},{"key":"378_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.euroneuro.2014.11.001","volume":"25","author":"E Palsson","year":"2015","unstructured":"Palsson, E. et al. Markers of glutamate signaling in cerebrospinal fluid and serum from patients with bipolar disorder and healthy controls. Eur. Neuropsychopharmacol. 25, 133\u2013140 (2015).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"378_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1503\/jpn.150093","volume":"41","author":"C Abe","year":"2016","unstructured":"Abe, C. et al. Cortical thickness, volume and surface area in patients with bipolar disorder types I and II. J. Psychiatry Neurosci. 41, 240\u2013250 (2016).","journal-title":"J. Psychiatry Neurosci."},{"key":"378_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery, S. A. & Asberg, M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382\u2013389 (1979).","journal-title":"Br. J. Psychiatry"},{"key":"378_CR25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1192\/bjp.133.5.429","volume":"133","author":"RC Young","year":"1978","unstructured":"Young, R. C., Biggs, J. T., Ziegler, V. E. & Meyer, D. A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133, 429\u2013435 (1978).","journal-title":"Br. J. Psychiatry"},{"key":"378_CR26","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/S0006-3223(03)00165-3","volume":"53","author":"GS Sachs","year":"2003","unstructured":"Sachs, G. S. et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol. Psychiatry 53, 1028\u20131042 (2003).","journal-title":"Biol. Psychiatry"},{"issue":"Suppl 20","key":"378_CR27","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan, D. V. et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59(Suppl 20), 22\u201333 (1998).","journal-title":"J. Clin. Psychiatry"},{"key":"378_CR28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/13803390490918444","volume":"27","author":"S Homack","year":"2005","unstructured":"Homack, S., Lee, D. & Riccio, C. A. Test review: Delis-Kaplan executive function system. J. Clin. Exp. Neuropsychol. 27, 599\u2013609 (2005).","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"378_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jad.2007.06.011","volume":"106","author":"M Berk","year":"2008","unstructured":"Berk, M. et al. The empirical redefinition of the psychometric criteria for remission in bipolar disorder. J. Affect Disord. 106, 153\u2013158 (2008).","journal-title":"J. Affect Disord."},{"issue":"Pt B","key":"378_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.neuropharm.2015.11.015","volume":"112","author":"AA Badawy","year":"2017","unstructured":"Badawy, A. A. Tryptophan availability for kynurenine pathway metabolism across the life span: Control mechanisms and focus on aging, exercise, diet and nutritional supplements. Neuropharmacology 112(Pt B), 248\u2013263 (2017).","journal-title":"Neuropharmacology"},{"key":"378_CR31","doi-asserted-by":"crossref","unstructured":"Chiappelli, J. et al. Neuropsychopharmacology. 43, 1675\u20131680 (2018).","DOI":"10.1038\/s41386-018-0038-4"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0378-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0378-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0378-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T15:21:44Z","timestamp":1671204104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0378-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,29]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["378"],"URL":"https:\/\/doi.org\/10.1038\/s41398-019-0378-9","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,29]]},"assertion":[{"value":"5 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.M.S. discloses lecture and consulting fees from Otsuka Pharmaceutical and H Lundbeck A\/S (none of these are relevant to this work). R.H.P. has served on scientific advisory boards or consulted to Genomind, Perfect Health, Psybrain, and RID Ventures (none of these are relevant to this work). S.E. discloses grant support from AstraZeneca and Jansen Pharmaceuticals as principal investigator and has been a speaker for Roche Pharmaceuticals, AstraZeneca, Eli Lilly, Orion Corporation Orion Pharma and Bristol Myers Squibb (none of these are relevant to this work). The remaining authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"37"}}